Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06942624

Phage Therapy for the Treatment of a Chronic Enterococcus Faecium Periprosthetic Joint Infection

This purpose of this clinical trial is to evaluate the safety, tolerability and efficacy of a bacteriophage therapy in a patient with a methicillin-susceptible Enterococcus faecium (E. faecium) prosthetic joint infection (PJI) of the hip. We have exhausted all surgical and medical management of PJI for our patient.

The phage will be administered to the study patient during a 14 days period via intravenous and intra-articular. The patient will be monitored in clinic for up to 1 year.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

About this study

This is a single-patient study, to assess a treatment option for a case of a recurrent methicillin-susceptible E. faecium infection in a prosthetic hip joint. The patient has repeatedly failed standard of care medical and surgical management.

Given the severity and chronicity of E. faecium infection and burden of infected hardware, the only option to achieve surgical source control would involve an aggressive, high risk surgical approach: a high amputation of the left leg to remove infected hardware and peri-implant bone and tissues. In the absence of any viable adjunctive antimicrobial therapy, this patient is at high risk of mortality and morbidity. It is therefore paramount that we explore alternative treatment modalities for the management of this infection, such as bacteriophage (phage) therapy.

The primary objective of this study is to investigate the preliminary efficacy, safety, and tolerability of systemic (intravenous) and intra-articular administration of a lytic phage (in our patient with chronic E. faecium PJI.

Secondary objectives will be documenting clinical changes pre- and post-therapy, as well as identifying adjunctive changes in biomarkers (C-reactive protein [CRP], erythrocyte sedimentation rate [ESR], and interleukin-6 [IL-6]) correlated with PJI as well as phage titres.

In this study, lytic phage prepared in injection-grade saline will be administered to the patient both intravenously and intraarticularly, twice a day for a duration of 14 days. In addition to phage therapy, the patient will receive standard of care antibiotic therapy.

The patient will remain in clinical follow-up for up to one year.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

This N-of-1 Phage therapy is designed for one patient who meet the following conditions

  • Willingness to provide signed and dated informed consent form to participate in the clinical study
  • Chronic prosthetic joint infection
  • History of multiple surgical and medication managements with no success

Exclusion criteria

  • below 18 years of age

Treatment and study plan

Phage therapy

Biological

Our phage is an investigational treatment for bacterial infections. Our lytic phage preparation was provided by Cytophage Technologies (CIP-200).

Primary outcomes

  1. Safety of phage therapy

    Time frame: Day 0 to 1 year from treatment

    Reactions and adverse events to the treatment

  2. Efficacy of phage therapy

    Time frame: 1 Year

    No recurrence of the infection

  3. Tolerability of phage therapy

    Time frame: Day 0 to Day 13 of treatment

    Reactions and adverse events to the intravenous and intra-articular administration

Secondary outcomes

  1. Changes in biomarkers (C-reactive protein)

    Time frame: Day 0 to 1 year from treatment

    Serum C-reactive protein (mg/L) as measured at baseline

  2. Changes in biomarkers (erythrocyte sedimentation rate)

    Time frame: Day 0 to 1 year from treatment

    Serum erythrocyte sedimentation rate (mm/hr) as measured at baseline

  3. Changes in biomarkers (interleukin-6)

    Time frame: Day 0 to 1 year from treatment

    Serum interleukin-6 (pg/mL) as measured at baseline

  4. Changes in biomarkers (phage titres)

    Time frame: Day 0 to Day 13 of treatment

    Phage particles present in a given volume of liquid (PFU/mL)

Study contacts

Contact information is provided by the study sponsor or research team.

Christiaan Righolt, PhD

CONTACT

[email protected]

204-926-1224

Sarah Tran

CONTACT

[email protected]

204-926-1231

Sponsors and collaborators

Lead sponsor

Orthopaedic Innovation Centre

Other

Collaborators

  • Cytophage Technologies Inc.
  • Ottawa Hospital Research Institute

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Apr 24, 2025
Registry last updated
Apr 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.